Regulation - Pricing, Rare diseases

Filter

Current filters:

PricingRare diseases

Popular Filters

Chiesi and uniQure delay Glybera launch to add data

Chiesi and uniQure delay Glybera launch to add data

04-08-2014

Netherlands-based venture capital backed human gene therapy firm uniQure and privately-held Italian drugmaker…

BiotechnologyChiesi FarmaceuticiEuropeGlyberaOrphan disease lipoprotein lipase deficiencyPricingRare diseasesRegulationuniQure

Orphan drug approvals rise, but high costs pose challenges for patients

Orphan drug approvals rise, but high costs pose challenges for patients

10-07-2014

Although the pace of approvals for new orphan drugs - medicines that treat relatively rare conditions…

EuropePharmaceuticalPricingRare diseasesRegulationUSA

Negative NICE appraisal of Pfizer’s Bosulif for CML

Negative NICE appraisal of Pfizer’s Bosulif for CML

27-11-2013

UK drug watchdog the National Institute for Health and Care Excellence (NICE) has issued final guidance…

BosulifEuropeOncologyPfizerPharmaceuticalPricingRare diseasesRegulation

UK's NICE calls for more data to consider Roche drug for a type of vasculitis

23-07-2013

UK drug watchdog the National Institute for Health and Care Excellence (NICE) has today (July 23) published…

BiotechnologyEuropeMabTheraOncologyPharmaceuticalPricingRare diseasesRegulationRoche

Celgene gets negative NICE view on Revlimid in rare blood cancer; presents new data in newly-diagnosed MM

11-07-2013

US biotech firm Celgene (Nasdaq: CELG) today (July 11) expressed disappointment at the preliminary decision…

BiotechnologyCelgeneEuropeOncologyPricingRare diseasesRegulationResearchRevlimid

New idiopathic pulmonary fibrosis treatment may open up valuable research opportunity, says GlobalData

17-04-2013

Further research is a prerequisite to shine a light on idiopathic pulmonary fibrosis (IPF) and offer…

BiotechnologyEsbrietInterMunePricingRare diseasesRegulationResearch

NICE "green light" for Novartis' Tobi Podhaler and Forest's Colobreathe

24-01-2013

The UK drugs watchdog the National Institute for Health and Clinical Excellence (NICE), in a final draft…

Antibiotics and Infectious diseasesColoBreatheEuropeForest LaboratoriesNovartisPharmaceuticalPricingRare diseasesRegulationTobi Podhaler

UK NICE agrees to reconsider decision to deny NHS access to GSK's Benlysta

07-09-2012

The UK drugs watchdog the National Institute for Health and Clinical Excellence (NICE) confirmed this…

Anti-Arthritics/RheumaticsBenlystaEuropeGlaxoSmithKlinePharmaceuticalPricingRare diseasesRegulation

Scottish regulator backs restricted NHS use of Janssen's Zytiga; negative on BioMarin's Firdapse

13-08-2012

The Scottish Medicines Consortium (SMC) announced yesterday that it has accepted Johnson & Johnson (NYSE:…

BioMarin PharmaceuticalEuropeFirdapseJanssenJohnson & JohnsonOncologyPharmaceuticalPricingRare diseasesRegulationZytiga

UK's NICE to takeover role of assessing high-cost rare disease drugs

25-07-2012

In the UK, the role of assessing very high cost drugs for people who suffer with rare conditions, under…

BiotechnologyEuropePharmaceuticalPricingRare diseasesRegulation

NICE now backs Xarelto to treat blood clots; negative on Bronchitol for CF

01-06-2012

In final draft guidance published today (1 June 1), UK drugs watchdog the National Institute for Health…

BayerBronchitolCardio-vascularEuropePharmaceuticalPharmaxisPricingRare diseasesRegulationRespiratory and PulmonaryXarelto

Germany's IQWiG finds in favor of Yervoy but not Benlysta or Fampyra

09-05-2012

The German Institute for Quality and Efficiency in Health Care (IQWiG) in the past few days issued a…

BenlystaBiogen IdecBiotechnologyBristol-Myers SquibbEuropeFampyraGlaxoSmithKlineNeurologicalOncologyPharmaceuticalPricingRare diseasesRegulationYervoy

UK NICE gives draft "No" to Benlysta, and negative final guidance for Tyverb and Herceptin

27-04-2012

There was a batch of bad news emanating from the US drugs watchdog the National Institute for Health…

Anti-Arthritics/RheumaticsBenlystaEuropeGlaxoSmithKlineHerceptinOncologyPharmaceuticalPricingRare diseasesRegulationRocheTyverb

Germany's IQWiG finds some benefit for Pfizer orphan drug Vyndaqel

11-04-2012

The German Institute for Quality and Efficiency in Health Care (IQWiG) has assessed Vyndaqel (tafamidis),…

EuropePfizerPharmaceuticalPricingRare diseasesRegulationVyndaqel

Portuguese hospitals block access to new medicines as retail drug sector expected to meet savings goal

30-09-2011

Access to expensive medicines is becoming increasingly difficult in Portuguese public hospitals, while…

EuropeHealthcarePfizerPharmaceuticalPricingRare diseasesRegulationVyndaqel

Back to top